usdaed

The current theory, as I understand it (and frankly, it changes hourly), is that companies are either going to build everything themselves (ambitious, but good luck with that) or AI is going to make all existing software redundant. Every time Anthropic announces something new with Claude, which apparently writes code better than most humans I know, SaaS stocks take a tumble. It’s a bit unsettling. I keep imagining a future where robots are running everything and I’m…well, I haven’t quite worked that part out yet.

The appeal of USD Coin lies in its grounding – a direct tether to the tangible assets of cash and United States Treasury obligations. This, in a world increasingly enamored of ethereal promises, is not insignificant. Many other such ‘stablecoins,’ as they are called, rest upon foundations of…shall we say, questionable solidity. Their claims of equivalence to the dollar are held aloft by hope and clever accounting, a precarious edifice easily toppled by a gust of skepticism. Circle, at least, offers the reassurance of something real beneath the digital surface.

He bought 2.67 million shares. Zero before, now… well, now there are 2.67 million. It’s over 11% of his Pershing Square portfolio. A large chunk. People are always looking for clues, for signals. Maybe this is one. Maybe it’s just a man making a bet. It often comes down to that, doesn’t it?

The quarterly report, a chronicle of endeavor, revealed a loss of twenty cents per share, but the story isn’t in the subtraction. It’s in the revenue – sixty-one million dollars – a sum that exceeded the anticipated harvest. The analysts, those weather-watchers of the financial seasons, had predicted forty million. This isn’t simply a matter of being ‘better than expected’; it is a demonstration of momentum, a gathering of force. A four-hundred and twenty-nine percent year-over-year increase isn’t a statistic; it’s an echo of growing demand, a whisper of the future becoming present.

They chase efficacy, these companies. A slightly superior percentage point of weight lost. As if the human body, with all its stubbornness and quiet rebellions, could be reduced to a simple equation. The trial, comparing CagriSema to Eli Lilly’s Zepbound, yielded a result. Not a catastrophe, not precisely. Just… a difference. A slight leaning in favor of the competitor. Enough, apparently, to shift the currents.

M/I Homes operates within a peculiar paradox: a housing shortage amidst a landscape of economic uncertainty. Demand, ostensibly, is robust. The Federal Reserve hints at easing interest rates, a siren song to potential homebuyers. Yet consumer prices remain elevated, stock market valuations flirt with the precarious, and the specter of tariffs and supply chain disruptions looms. A volatile brew, indeed.

Today, however, this little coin is doing a bit of a wobble. Down 5.2% it’s slipped, as of a few moments ago. Not a disaster, mind you, but enough to raise an eyebrow. Especially when you consider everything else that’s been happening.

The question, of course, is whether this momentum can be maintained. Predicting the future is, as anyone who’s tried it will tell you, a fool’s errand. But we can make informed guesses, and over the next five years, AbbVie has a few tricks up its sleeve, or, more accurately, in its pipelines. Let’s have a look.

Units of GitLab shares sold: 192,532. Hours spent staring at the trading screen today: 7. Number of times I questioned my life choices: immeasurable.

According to the people who track these things (S&P Global Market Intelligence, shoutout to them!), IonQ is up a respectable 30.8% since last Friday. Which, in the stock market, is basically like winning the lottery… if the lottery paid out in slightly-less-terrifying financial instruments.